Stewart WC, Stewart JA, Crockett S, Kubilus C, Brown A, Shams N. Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test.
ACTA OPHTHALMOLOGICA SCANDINAVICA 2002;
80:272-6. [PMID:
12059865 DOI:
10.1034/j.1600-0420.2002.800308.x]
[Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
PURPOSE
To compare the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test.
METHODS
Thirty subjects aged 18-37 years (mean age = 24.1 years) were randomized to one of six treatment sequences in a three-treatment, three-period crossover study (William's design). Study medication was instilled b.i.d. for 5 days before visits 2, 3, and 4. Between treatments, study medication was washed out for 9-10 days. Each subject underwent a submaximal treadmill test at visits 2 through 4, 15 min after dosing.
RESULTS
After 15 min of exercise, average heart rates were 143.1 +/- 21.2, 134.5 +/- 20.0 and 145.4 +/- 20.8 bpm for the unoprostone, timolol and placebo treatments, respectively. At no timepoint was there a statistically significant difference between the unoprostone and placebo treatments (p > 0.05). Beginning with the second minute of exercise, timolol produced a greater decrease in heart rate at all timepoints from placebo than unoprostone (p < 0.05). No consistent differences in systolic or diastolic blood pressure were observed between drug treatments (p > 0.05).
CONCLUSIONS
Unlike timolol, unoprostone 0.15% does not reduce exercise-induced heart rate, indicating a lack of clinical effect on systemic beta-adrenergic receptors in young and healthy subjects.
Collapse